> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Janssen Discontinues Development of Osteoarthritis Pain Therapy
- URL: https://www.fdaweb.com/janssen-discontinues-development-of-osteoarthritis-pain-therapy/
- Published: 2016-04-01T12:00:00.000Z
- Updated: 2026-09-14T20:52:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135248

> Janssen Research & Development says it is discontinuing a Phase 3 development program for fulranumab in osteoarthritis pain. The decision was based on “strategic portfolio prioritization and was not based on any emerging safety concerns from the Phase 3 clinical studies with fulranumab,” it says. Additionally, affiliate Janssen Pharmaceuticals is terminating its licensing agreement with Amgen on fulranumab and is returning all program rights back to Amgen. Fulranumab is part of an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds. In 2008, Amgen licensed the therapy to Ortho-McNeil-Janssen Pharmaceuticals, which is now known as Janssen Pharmaceuticals.